Gigacloud Technology Inc vs Zoetis Inc — how do they compare? Gigacloud Technology Inc trades at $57.26 (market cap $2.02B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 15× Gigacloud Technology Inc's market cap, and Zoetis Inc pays a 2.9% dividend while Gigacloud Technology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gigacloud Technology Inc for 21 Days and Zoetis Inc for 70 Days on average.
| GCT | ZTS | |
|---|---|---|
Market Cap | $2.02B | $30.20B |
Volume | 1,020,985 | 6,175,327 |
Sector | Technology | Health |
52-Week High | $56.42 | $147.53 |
52-Week Low | $25.46 | $69.09 |
Typical Hold Time | 21 Days | 70 Days |
Enterprise Value | $2.14B | $37.76B |
Dividend Yield | — | 2.9% |
Signals from Pluang's Aura AI — not financial advice
GCT trades at $57.26, up 2.32% today, with a bullish technical outlook and strong earnings momentum after beating EPS estimates for three consecutive quarters. The stock shows robust profitability with a 10.65% net income margin and 32.34% ROE, supported by positive cash flow from operations of $190.66 million in 2025. Recent news highlights institutional interest and expansion into European markets.
The outlook is positive with revenue growth to $1.5 billion projected for 2026 and a consensus analyst price target of $32.50, though risks include insider selling and competitive pressures in the consumer discretionary sector. The stock's current price near resistance at $58 suggests potential for volatility amid overbought short-term conditions.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Trailing returns across standard periods
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →